Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Opportunities to Optimize Cancer Policies Panel Discussion

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Advertisement

Advertisement




May
08
Today In Oncology
Bavituximab Plus Pembrolizumab for Patients With Hepatocellular Carcinoma
Effects of Radiation Therapy Timing on Lifespan of Artificial Urinary Sphincters in Prostate Cancer Survivors
Hemihepatectomy Outcomes With Laparoscopic vs Open Surgery
T-DXd vs Physicians Choice of Therapy in HER2-Positive Metastatic Breast Cancer PROs in DESTINY-Breast02
Novel Urine Biomarker Test May Reduce Unnecessary Cystoscopies in Patients With Bladder Cancer
View More 
Advertisement
© 2024 HSP News Service, L.L.C.
Designed by Harborside